A second-generation recombinant BCG strain combines protection against murine tuberculosis with an enhanced safety profile in immunocompromised hosts
Vaccine, ISSN: 0264-410X, Vol: 42, Issue: 24, Page: 126291
2024
- 7Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures7
- Readers7
- Mentions1
- News Mentions1
- 1
Most Recent News
Investigators from James Cook University Release New Data on Tuberculosis (A Second-generation Recombinant Bcg Strain Combines Protection Against Murine Tuberculosis With an Enhanced Safety Profile In Immunocompromised Hosts)
2024 OCT 29 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Life Science Daily -- New research on Mycobacterium Infections - Tuberculosis is
Article Description
Bacille Calmette-Guérin (BCG) remains the only licensed vaccine against tuberculosis (TB). While BCG protects against TB in children, its protection against pulmonary TB in adults is suboptimal, and the development of a better TB vaccine is a global health priority. Previously, we reported two recombinant BCG strains effective against murine TB with low virulence and lung pathology in immunocompromised mice and guinea pigs. We have recently combined these two recombinant BCG strains into one novel vaccine candidate (BCGΔBCG1419c::ESAT6-PE25SS) and evaluated its immunogenicity, efficacy and safety profile in mice. This new vaccine candidate is non-inferior to BCG in protection against TB, presents reduced pro-inflammatory immune responses and displays an enhanced safety profile.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0264410X24009733; http://dx.doi.org/10.1016/j.vaccine.2024.126291; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85203011074&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/39241355; https://linkinghub.elsevier.com/retrieve/pii/S0264410X24009733
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know